Xanadu Quantum reports first public-company quarter: Q1 2026 revenue of $2.8M (+4x YoY) with widened $20.6M net loss, $272.5M cash; announces $300M synthetic ATM facility
On 2026-05-14 Xanadu Quantum Technologies Limited (Nasdaq: XNDU; TSX: XNDU) released its inaugural quarterly results as a public company in a Form 6-K filing covering the three months ended 2026-03-31. Revenue was $2.8M USD, up approximately 4x from $0.7M USD in Q1 2025, driven primarily by US military-backed quantum research-program participation. Net loss widened to $20.6M USD ($0.28 per share) from $12.2M USD ($0.22 per share) in Q1 2025 - a $0.28 EPS print versus the $0.08 consensus estimate, an approximately 3.5x miss. Adjusted EBITDA loss was $13.9M USD, driven by higher research-and-development and general-and-administrative expense as the business scales. Cash and cash equivalents stood at $272.5M USD at quarter-end, reflecting the 2026-03-27 reverse recapitalization with Crane Harbor Acquisition Corp. and concurrent PIPE financing that delivered approximately $301.6M USD in gross proceeds. Concurrent with the earnings release, Xanadu announced plans to establish a $300M USD synthetic at-the-market (ATM) facility, designed to allow the company to issue Class B subordinate voting shares over time in private placements at its discretion, subject to applicable stock-exchange approval. Net proceeds would be applied to fund continued development of the company's photonic quantum-computing technology roadmap.
Score 6. §8.2 anchor row 6 'Quarterly revenue beat or miss by a meaningful margin for a tracked public name' is the structural anchor: revenue beat consensus ($2.8M vs. estimate band; +4x YoY), but EPS missed consensus by approximately 3.5x ($0.28 net-loss-per-share vs. $0.08 estimate). The print is the company's first as a public name and resets the public-company financial baseline for a pure-play photonic quantum competitor. Score held at 6 rather than 7 because (a) the absolute scale of both revenue ($2.8M) and net loss ($20.6M) is small relative to the trailing-quarter peer cohort (IonQ Q1 2026 $64.7M revenue scored 7; D-Wave Q1 2026 $33.4M bookings scored 7), and the print does not constitute an 'unexpected corporate action' in the §8.2 row-7 sense; (b) the announced $300M synthetic ATM facility is a meaningful capital-structure disclosure but typical for a recently de-SPAC'd small-cap and does not itself trigger a separate score-7 'shelf offering' anchor — the synthetic-ATM mechanism in private-placement form is distinct from a public shelf-registration secondary; (c) operational continuity is intact ($272.5M cash provides multi-year runway at current burn). The print is held above 5 because the EPS miss is material relative to consensus, the synthetic-ATM disclosure adds a forward dilution vector worth tracking, and Xanadu is one of three pure-play quantum companies (IonQ, D-Wave, Xanadu) reporting Q1 2026 results within a single trailing-10-day window — the print closes the listed-pure-play Q1 2026 cohort with the smallest revenue base.
The Xanadu Q1 print extends the listed-quantum-Q1-2026-earnings-cluster open thread to a five-name cohort (IonQ, D-Wave, Rigetti, QUBT, Xanadu - Quantinuum not yet listed and reports on its own S-1 prospectus calendar; Arqit's H1 FY2026 also separately reported 2026-04-10). The synthetic-ATM facility introduces a forward-dilution thread for the public-pure-play cohort: the 2026-05-04 Xanadu 424B3 share-resale registration filing (which scored 7) created the existing dilution-overhang thread; the 2026-05-14 $300M synthetic-ATM disclosure materially extends that thread by adding a discretionary issuance mechanism over and above the previously-registered selling-securityholder shares. Watch for: (a) Q2 2026 print whether the US military-backed quantum-research-program revenue is recurring or one-time and whether enterprise commercial bookings appear; (b) synthetic-ATM stock-exchange approval timeline (Nasdaq and TSX, both required given the dual listing); (c) the cadence and pricing of any synthetic-ATM share issuances after approval; (d) Lockheed Martin's 5.1% Schedule 13G filer's posture - whether it remains passive or develops into a binding commercial relationship; (e) photonic-modality peer Q1/Q2 2026 disclosures from PsiQuantum (still private), Quandela, and Photonic Inc. (still private, $200M USD close 2026-05-12); (f) the relative valuation impact on Xanadu given the IQM F-4 announced today at $1.8B pre-money - both photonic-vs-superconducting cross-modality and pre-public-vs-post-public valuation comparisons are now newly available.